Navigation Links
M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting


VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that the University of Texas M. D. Anderson Cancer Center's abstract, "Inhibition of primary growth and distant metastasis with a CXCR4 antagonist in a mouse model of breast cancer" authored by Eugene H. Huang, Balraj Singh, Laura Vincent, Massimo Cristofanilli, Kailash Mosalpuria, Caimiao Wei, and Anthony Lucci, has been accepted by the American Association for Cancer Research ("AACR") for oral presentation at its 2007 Annual Meeting being held in Los Angeles, California. The presentation will be given by Dr. Eugene Huang on Wednesday, April 18, 2007, as part of the Experimental Therapeutics Mini-symposium.

The Meeting is expected to attract more than 15,000 participants from 60 countries to discuss and hear presentations on new and significant discoveries in basic, clinical, and translational cancer research. The AACR hopes to identify the most compelling science and ensure that the latest advances in all areas of cancer research and specifically the most important emerging research fields are fully covered.

Researchers at the M. D. Anderson Cancer Center have been studying the ability of CTCE-9908 to inhibit the metastasis of a human breast cancer in preclinical models as part of a collaborative research effort with the Company.

About CTCE-9908

CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on cancer cells of over 30 different tumor types. Activation by SDF-1 is believed to be critical in angiogenesis and in the metastasis (or spread) of cancer cells to distant locations in the body, where they form new tumors. Approximately 90% of cancer deaths are due to metastasis. We believe that CTCE-9908 interferes with the metastatic process of cancers by both preventing their spread and blocking the blood supply to the cancer cells.

The Company is currently conducting a Phase Ib/II clinical trial on CTCE-9908 to assess safety and preliminary efficacy in late stage cancer patients. Preliminary results were recently released where no dose limiting toxicities were observed in any of the cancer patients and two out of three patients with ovarian cancer responded positively and exhibited stable disease when comparing the size of target tumors at baseline to the assessment performed after CTCE-9908 treatment. The remaining patients are currently being enrolled with the final results expected later this year.

About American Association for Cancer Research

AACR is one of the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

About The University of Texas M. D. Anderson Cancer Center

M. D. Anderson Cancer Center, a component of The University of Texas System, has established an international reputation as one of the world's preeminent centers for cancer patient care, research, education and prevention with pioneering approaches and technologies. M. D. Anderson holds the distinction of being designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. M. D. Anderson has been named the nation's top cancer hospital by U.S. News & World Report's "Best Hospit als" survey four out of the past six years.

About Chemokine Therapeutics Corp.

Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of an y financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of Public Relations, Phone: (604) 822-0305, or 1-888-822-0305, Fax: (604) 822-0302, E-mail: , Internet:; Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax: (416) 815-0080, E-mail:

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of PublicRelations, Phone: (604) 822-0305, or 1-888-822-0305, Fax: (604) 822-0302,E-mail: , Internet:; Equicom Group,Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax:(416) 815-0080, E-mail:

Ticker Symbol: (Toronto:CTI.),(NASDAQ-OTCBB:CHKT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Protox Announces Positive Clinical Data from Prostate Cancer Study
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
Breaking Medicine Technology:
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... ... is the first health care provider in the region to offer the vBloc® Therapy ... vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients over ... to 45 kg, or a BMI of at least 35 to 39.9 kg with a ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
Breaking Medicine News(10 mins):